NDAINJECTION, ORALSOLUTION
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Pertechnetate Tc-99m is a radioactive diagnostic imaging agent used for nuclear medicine procedures. It is a technetium-based radiopharmaceutical that localizes to specific tissues and organs, enabling visualization via gamma camera imaging. The drug is administered via injection or oral route depending on the diagnostic indication.
LOE Approaching
As an aging diagnostic product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams face resource constraints and declining commercial opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product presents minimal career advancement opportunities, with zero currently linked job openings. Career roles are primarily focused on maintenance, compliance, and operational continuity rather than commercial growth or innovation.
Regulatory Affairs SpecialistQuality Assurance Manager
Worked on SODIUM PERTECHNETATE TC 99M at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.